August 18, 2025

Sarah Cannon Research Institute Expands Leadership Team with the Appointment of Sarah Premji, MD, as Assistant Director of Breast Cancer Research

Nashville, TN – August 18, 2025 – Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, is proud to announce the appointment of Sarah Premji, MD, as Assistant Director of Breast Cancer Research. Dr. Premji joins SCRI with a background in academic medicine, clinical research, and patient-centered oncology care, with a particular focus on breast cancer. In her leadership role at SCRI, Dr. Premji will support breast cancer research operations across SCRI’s network of more than 200 locations. Dr. Premji will also serve as a medical oncologist at SCRI Oncology Partners, a practice in The US Oncology Network in Nashville, Tenn., starting on September 8.

“We are excited to welcome Dr. Premji to our research leadership team,” said David Spigel, MD, Chief Scientific Officer of SCRI and medical oncologist at SCRI Oncology Partners. “Her clinical insight and commitment to innovation will be instrumental in advancing our breast cancer research program and improving outcomes for patients.”

Dr. Premji is board certified in internal medicine and completed a hematology/oncology fellowship at Mayo Clinic, where she was recognized with several awards for her leadership and research contributions. She completed an internal medicine residency at Baylor College of Medicine, earned a medical degree from the Medical College of Georgia, and holds a Bachelor of Science in biology and psychology from the University of Georgia Honors Program.

A recipient of the 2025 American Society of Clinical Oncology (ASCO) Conquer Cancer Young Investigator Award, Dr. Premji has authored numerous peer-reviewed publications and presented her work at leading national and international oncology conferences. She is working towards building her career in clinical research and was selected to attend the prestigious ASCO/AACR Methods in Clinical Cancer Research Workshop — formerly known as the Vail Workshop — recognized for its rigorous training and impact on advancing cancer research.

Dr. Premji is also actively involved in national advocacy and mentorship efforts, serving on ASCO’s Trainee and Early Career Advisory Group and the Minnesota Society of Clinical Oncology’s Advocacy Group among others.

Dr. Premji will begin her positions at both SCRI and SCRI Oncology Partners on September 8.

About Sarah Cannon Research Institute (SCRI)

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at over 200 locations in more than 20 states across the U.S. Learn more about our research offerings.

Media Contact

SCRI
Becca Gelman
Becca.Gelman@scri.com